ASCEMBL: Phase III Study of STAMP Inhibitor Asciminib vs Bosutinib for CML-CP Previously Treated With ≥ 2 TKIs

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
At Week 24, asciminib significantly improved MMR rate compared with bosutinib (25.5% vs 13.2%, respectively) with numerically lower rates of AEs leading to discontinuation, dose adjustment, or the requirement for additional therapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 222 KB
Released: December 14, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seagen
Takeda Oncology

Related Content

Downloadable slides on recent updates in R/R FL, with a focus on bispecific antibodies and CAR T-cell therapy, from Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Laurie H. Sehn, MD, MPH Released: February 2, 2023

Downloadable slides on recent updates in R/R FL, with a focus on second-line therapies and third-line epigenetic modifiers and PI3K inhibitors, from Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Laurie H. Sehn, MD, MPH Released: February 2, 2023

On-demand webcast from an ASH 2022 satellite symposium on BTK inhibitors for patients with CLL and MCL, from Clinical Care Options (CCO)

Jeff Sharman, MD
Program Director
Ian W. Flinn, MD, PhD Susan M. O'Brien, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 31, 2023 Expired: January 30, 2024

On-demand Clinical Care Options (CCO) webcast from a December 2022 symposium: experts discuss new care standards and evolving treatment strategies for aggressive B-cell lymphomas

John P. Leonard, MD
Program Director
John Allan, MD Laurie H. Sehn, MD, MPH
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 30, 2023 Expired: January 29, 2024

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings